On Friday, Xencor reached an important technical milestone, with its Relative Strength (RS) Rating rising into the 80-plus percentile with an improvement to 83, a rise from 80 the day before.
IBD's unique RS Rating tracks technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the trailing 52 weeks matches up against that of all other stocks.
Decades of market research reveals that the stocks that go on to make the biggest gains often have an 80 or better RS Rating as they begin their biggest runs.
Risk Management In The Stock Market: How Much Money To Invest Now
While now is not an ideal time to invest, see if the stock is able to establish and enter a buying range in heavy volume.
The company reported 0% EPS growth last quarter. Sales increased -82%.
The company earns the No. 211 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Neurocrine Biosciences are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
